CFO Peter J. Mariani Buys $44,000 in Open Market Amidst Delisting Concerns
CTSO sits 23% above its 52-week low of $0.37 on elevated volume (2.2× avg).
Summary
Cytosorbents' CFO Peter J. Mariani purchased $44,000 of company stock in the open market, signaling management confidence as the company faces a potential delisting and a shareholder vote on a reverse stock split.
Key Events · Ownership and Investor Activity · CTSO
-
CFO Open Market Purchase
Chief Financial Officer Peter J. Mariani acquired 100,000 shares for $44,000 in an open market transaction on June 15, 2026.
-
Cluster Insider Buying
This purchase follows a $104,898 open market buy by CEO Phillip P. Chan on the same day, indicating a cluster of insider accumulation.
-
Context of Financial Distress
The insider buying occurs amidst a Nasdaq delisting threat, a going concern warning, and a pending shareholder vote on a reverse stock split, making the show of confidence more notable.
Analysis · CTSO · Industrial Applications And Services
The CFO's open market purchase of $44,000, following a similar purchase by the CEO on the same day, signals management's conviction in the company's future despite significant challenges. Cytosorbents is currently facing a Nasdaq delisting threat, a going concern warning, and recently reported a widened net loss, with shareholders set to vote on a reverse stock split. These cluster insider buys suggest a belief that the company can navigate its current difficulties.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 29.4% of the 1563 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTSO was trading at $0.45 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $27.1M. The 52-week trading range was $0.37 to $1.39. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.